NCT01634685View on ClinicalTrials.gov

A Phase I Study of Bavituximab, Capecitabine, and Radiation for the Treatment of Rectal Adenocarcinoma

PHASE1CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

August 8, 2012

Primary Completion Date

October 30, 2015

Study Completion Date

October 6, 2017

Conditions
Rectal Adenocarcinoma
Interventions
RADIATION

Radiation

Radiation therapy will be administered daily, Monday-Friday, for a total of 28 treatments, delivered at 1.8 Gy/fraction.

DRUG

Bavituximab

Bavituximab will be delivered concurrently with the radiation therapy for 6 weeks (one time each week), followed by 2 weeks of bavituximab administration by itself.

DRUG

Capecitabine

capecitabine, will be delivered twice daily p.o. on the days of radiation treatment, at a dose of 825 mg/m2.

Trial Locations (1)

75390

University of Texas Southwestern Medical Center, Dallas

All Listed Sponsors
lead

University of Texas Southwestern Medical Center

OTHER

NCT01634685 - A Phase I Study of Bavituximab, Capecitabine, and Radiation for the Treatment of Rectal Adenocarcinoma | Biotech Hunter | Biotech Hunter